Enanta Pharmaceuticals Stock Performance
| ENTA Stock | USD 13.91 0.35 2.58% |
On a scale of 0 to 100, Enanta Pharmaceuticals holds a performance score of 5. The firm shows a Beta (market volatility) of 1.86, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enanta Pharmaceuticals will likely underperform. Please check Enanta Pharmaceuticals' sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Enanta Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, Enanta Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.58 | Five Day Return 11.46 | Year To Date Return 38 | Ten Year Return (60.87) | All Time Return (19.03) |
1 | Enanta Pharmaceuticals Fiscal Q1 Earnings Snapshot | 02/07/2024 |
2 | Acquisition by Nathaniel Gardiner of 5187 shares of Enanta Pharmaceuticals at 8.99 subject to Rule 16b-3 | 02/26/2024 |
3 | Trexquant Investment LP Takes Position in Enanta Pharmaceuticals, Inc. - MarketBeat | 03/04/2024 |
4 | Acquisition by Bruce Carter of 15700 shares of Enanta Pharmaceuticals at 15.66 subject to Rule 16b-3 | 03/06/2024 |
5 | Liver drug developers gain as U.S. awaits first NASH drug | 03/13/2024 |
6 | Short Interest in Enanta Pharmaceuticals, Inc. Drops By 5.4 percent - MarketBeat | 03/18/2024 |
7 | Acquisition by Foletta Mark G of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3 | 03/22/2024 |
8 | Enanta Pharmaceuticals, Inc. Sees Significant Growth in Short Interest - MarketBeat | 04/02/2024 |
9 | Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 - Yahoo Finance | 04/17/2024 |
10 | Insider Trading | 04/29/2024 |
11 | Acquisition by Paul Mellett of 10440 shares of Enanta Pharmaceuticals at 14.0 subject to Rule 16b-3 | 05/01/2024 |
| Begin Period Cash Flow | 48 M |
Enanta |
Enanta Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,237 in Enanta Pharmaceuticals on February 3, 2024 and sell it today you would earn a total of 154.00 from holding Enanta Pharmaceuticals or generate 12.45% return on investment over 90 days. Enanta Pharmaceuticals is currently generating 0.2601% in daily expected returns and assumes 3.8291% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Enanta, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enanta Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enanta Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enanta Pharmaceuticals, and traders can use it to determine the average amount a Enanta Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0679
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENTA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.83 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Enanta Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enanta Pharmaceuticals by adding it to a well-diversified portfolio.
Enanta Pharmaceuticals Fundamentals Growth
Enanta Stock prices reflect investors' perceptions of the future prospects and financial health of Enanta Pharmaceuticals, and Enanta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enanta Stock performance.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (1.94) % | ||||
| Current Valuation | 164.76 M | ||||
| Shares Outstanding | 21.16 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 4.73 X | ||||
| Revenue | 79.2 M | ||||
| Gross Profit | 86.16 M | ||||
| EBITDA | (123.48 M) | ||||
| Net Income | (133.82 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | (103.15 M) | ||||
| Earnings Per Share | (6.57) X | ||||
| Market Capitalization | 286.88 M | ||||
| Total Asset | 462.27 M | ||||
| Retained Earnings | (207 M) | ||||
| Working Capital | 360 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
About Enanta Pharmaceuticals Performance
To evaluate Enanta Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Enanta Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Enanta Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Enanta Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Enanta's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.32) | (0.31) | |
| Return On Capital Employed | (0.39) | (0.38) | |
| Return On Assets | (0.33) | (0.32) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Enanta Pharmaceuticals performance evaluation
Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enanta Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22. | |
| Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Paul Mellett of 10440 shares of Enanta Pharmaceuticals at 14.0 subject to Rule 16b-3 |
- Analyzing Enanta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enanta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Enanta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enanta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enanta Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enanta Pharmaceuticals' stock. These opinions can provide insight into Enanta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Enanta Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (6.57) | Revenue Per Share 3.5 | Quarterly Revenue Growth (0.24) | Return On Assets (0.23) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.